Vir Biotechnology is a biotech headquartered in US. Over the past three years, Vir Biotechnology has been involved in 4 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals). The company currently has 9 active clinical trials, primarily in Infectious.
Deals (12mo)
2
Active Trials
9
Top Modality
Bispecific Antibodies
Focus Area
Infectious
Licensing, acquisition, and partnership transactions involving Vir Biotechnology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| VIR-5500 | Astellas Pharma | Bispecific Antibodies | Phase 1 | collaboration | Feb 24, 2026 |
| tobevibart + elebsiran | Norgine Pharma UK Limited | Other | Phase 2 | license | Dec 15, 2025 |
Therapeutic areas and modalities where Vir Biotechnology is most active based on deal history and clinical trial data.
Key indicators of Vir Biotechnology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Vir Biotechnology has 9 active clinical trials across 4 development phases.
2
Phase 1
1
Phase 1/2
3
Phase 2
3
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Vir Biotechnology is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Vir Biotechnology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Vir Biotechnology include Infectious (6 deals and trials), Oncology (4 deals and trials), Infectious Disease (2 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Vir Biotechnology has shown particular interest in bispecific antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Vir Biotechnology and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Vir Biotechnology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.